Teva- Pharmaceutical Industries Ltd

Research Teva- Pharmaceutical Industries Ltd (TEVA) on Bullrun: valuation model: 7.9% undervalued, market cap USD 38.77B, P/E 24.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerTEVA
ExchangeNYSE
CountryIsrael
SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic
CurrencyUSD
Valuation signal7.9% undervalued
Market capUSD 38.77B
P/E24.8
Financial periodFY2025
RevenueUSD 17.26B
Revenue growth4.3%
Net incomeUSD 1.41B
Free cash flowUSD 1.15B
Gross margin51.8%

Valuation Snapshot

Bullrun's latest valuation model marks Teva- Pharmaceutical Industries Ltd as 7.9% undervalued; latest market cap is USD 38.77B; P/E is 24.8.

About Teva- Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms;

Frequently asked questions

Is Teva- Pharmaceutical Industries Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Teva- Pharmaceutical Industries Ltd as 7.9% undervalued.

What is Teva- Pharmaceutical Industries Ltd's market cap?

Teva- Pharmaceutical Industries Ltd's market capitalization is USD 38.77B.

What is Teva- Pharmaceutical Industries Ltd's P/E ratio?

Teva- Pharmaceutical Industries Ltd's price-to-earnings (P/E) ratio is 24.8.